Adaptive designs for subpopulation analysis optimizing utility functions

Biometrical Journal

Volumn 57, Issue 1, 2015, Pages 76-89

  Graf, Alexandra C ^a,b   Posch, Martin ^a   Koenig, Franz ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF BREMEN   (Germany)

Author keywords

Adaptive design; Enrichment design; Hypothesis selection; Sample size reallocation; Utility function

Indexed keywords

PATIENT TREATMENT; RISK ASSESSMENT;

ADAPTIVE DESIGNS; BENEFIT/RISK; ENRICHMENT DESIGN; HYPOTHESIS SELECTION; SAMPLE SIZE REALLOCATION; SAMPLE SIZES; SUB-POPULATIONS; TREATMENT EFFECTS; TYPE OF RISKS; UTILITY FUNCTIONS;

BIOMARKERS;

BIOLOGICAL MARKER;

BIOMETRY; CLINICAL TRIAL (TOPIC); HUMAN; METABOLISM; PROCEDURES; RISK ASSESSMENT; TREATMENT OUTCOME;

BIOMARKERS; BIOMETRY; CLINICAL TRIALS AS TOPIC; HUMANS; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 84920889664     PISSN: 03233847     EISSN: 15214036     Source Type: Journal    
DOI: 10.1002/bimj.201300257     Document Type: Article

References (41)

1. Alosh, M. and Huque, M. (2009). A flexible strategy for testing subgroups and overall populations. Statistics in Medicine 28, 2-23.
2. Bauer, P. and Kieser, M. (1999). Combining different phases in the development of medical treatments within a single trial. Statistics in Medicine 18, 1833-1848.
3. Bauer, P. and Koehne, K. (1994). Evaluations of experiments with adaptive interim analysis. Biometrics 50, 1029-1041.
4. Bauer, P. and Koenig, F. (2014). The risks of methodology aversion in drug regulation. Nature Reviews Drug Discovery 13, 317-318.
5. Beckman, R., Clark, J. and Chen, C. (2011). Integrating predictive biomarkers and classifiers into oncology clinical development programmes. Nature Reviews Drug Discovery 10, 735-748.
6. Boessen, R., van der Baan, F., Groenwold, R., Egberts, A., Klungel, O., Grobbee, D., Knol, M. and Roes, K. (2013). Optimizing trial design in pharmacogenetics research: comparing a fixed parallel group, group sequential, and adaptive selection design on sample size requirements. Parmaceutical Statistics, 12, 366-374.
7. Brannath, W., Zuber, E., Branson, M., Bretz, F., Gallo, P., Posch, M. and Racine-Poon, A. (2009). Confirmatory adaptive designs with Bayesian decision tools for a targeted therapy in oncology. Statistics in Medicine 28, 1445-1463.
8. Bretz, F., Koenig, F., Brannath, W., Glimm, E. and Posch, M. (2009). Adaptive designs for confirmatory clinical trials. Statistics in Medicine 28, 1181-1217.
9. Chen, C. and Beckman, R. (2009). Hypothesis testing in a confirmatory Phase III trial with a possible subset effect. Statistics in Biopharmaceutical Research 1, 431-440.
10. Eichler, H.-G., Bloechl-Daum, B., Brasseur, D., Breckenridge, A., Leufkens, H., Raine, J., Salmonson, T., Schneider, C. and Rasi, G. (2013). The risks of risk aversion in drug regulation. Nature Reviews Drug Discovery 12, 907-916.
11. EMA European Medicines Agency (2010). Concept paper on the need for a guideline on the use of subgroup analyses in randomised controlled trials. Doc. Ref. EMA/CHMP/EWP/117211/2010, available on http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/05/WC500090116.pdf
12. EMA European Medicines Agency (2011). Benefit-risk methodology project, work package 3 report: Field tests, available on http://www.ema.europa.eu/docs/en_GB/document_library/Report/2011/09/WC500112088.pdf
13. Freidlin, B. and Korn, E. (2014). Biomarker enrichment strategies: matching trial design to biomarker credentials. Nature Reviews Clinical Oncology 11, 81-90.
14. Freidlin, B., McShane, L. M. and Korn, E. L. (2013). Randomized clinical trials with biomarkers: design issues. Journal of the National Cancer Institute 102, 152-160.
15. Freidlin, B. and Simon, R. (2005). Adaptive signature design: an adaptive clinical trial design for generating and prospectively testing a gene expression signature for sensitive patients. Clinical Cancer Research 11, 7872-7878.
16. Friede, T., Parsons, N. and Stallard, N. (2012). A conditional error function approach for subgroup selection in adaptive clinical trials. Statistics in Medicine 31, 4309-4320.
17. Hirth, R., Chernew, M., Miller, E., Fendrick, A. and Weissert, W. (2000). Willingness to pay for a quality-adjusted life year in search of a standard. Medical Decision Making 20, 332-342.
18. Hochberg, Y. (1988). A sharper Bonferroni procedure for multiple tests of significance. Biometrika 75, 227-244.
19. Hommel, G. (2001). Adaptive modifications of hypotheses after and interim analysis. Biometrical Journal 43, 581-589.
20. Jenkins, M., Stone, A. and Jennison, C. (2011). An adaptive seamless phase II/III design for oncology trials with subpopulation selection using correlated survival endpoints. Pharmaceutical Statistics 10, 347-356.
21. Jiang, W., Freidlin, B. and Simon, R. (2007). Biomarker-adaptive threshold design: a procedure for evaluating treatment with possible biomarker-defined subset effect. Journal of the National Cancer Institute 99, 1036-1043.
22. Kelly, P. J., Stallard, N. and Todd, S. (2005). An adaptive group sequential design for phase II/III clinical trials that select a single treatment from several. Journal of Biopharmaceutical Statistics 15, 641-658.
23. Lehmacher, W. and Wassmer, G. (1999). Adaptive sample size calculations in group sequential trials. Biometrics 55, 1286-1290.
24. Magnusson, B. P. and Turnbull, B. W. (2013). Group Sequential enrichment design incorporating subgroup selection. Statistics in Medicine 32, 2695-2714.
25. Maitournam, A. and Simon, R. (2005). On the efficiency of targeted clinical trials. Statistics in Medicine 24, 329-339.
26. Mandrekar, S. J. and Sargent, D. J. (2009a). Clinical trial designs for predictive biomarker validation: one size does not fit all. Journal of biopharmaceutical statistics 19, 530-542.
27. Mandrekar, S. J. and Sargent, D. J. (2009b). Clinical trial designs for predictive biomarker validation: theoretical considerations and practical challenges. Journal of Clinical Oncology 27, 4027-4034.
28. Marcus, R., Peritz, E. and Gabriel, K. (1976). On closed testing procedures with special reference to order analysis of variance. Statistics in Medicine 63, 665-660.
29. Mehta, C., Gao, P. and Bhatt, D. L., Harrington, R. A., Skerjanec, S. and Ware, J. H. (2009). Optimizing trial design: sequential, adaptive, and enrichment strategies. Circulation 119, 597-605.
30. Millen, B. A., Dmitrienko, A., Ruberg, S. and Shen, L. (2012). A statistical framework for decision making in confirmatory multipopulation tailoring clinical trials. Drug Information Journal 46, 647-656.
31. Mueller, H. H. and Schaefer, H. (2001). Adaptive group sequential designs for clinical trials: combining the advantages of adaptive and of classical group sequential approaches. Biometrics 95, 886-891.
32. Mueller, H. H. and Schaefer, H. (2004). A general statistical principle for changing a design any time during the course of a trial. Statistics in Medicine 23, 2497-2508.
33. Posch, M. and Bauer, P. (2013). Adaptive budgets in clinical trials. Statistics in Biopharmaceutical Research 5, 282-292.
34. Sargent, D. and Mandrekar, S. (2013). Statistical issues in the validation of prognostic, predictive and surrogate biomarkers. Clinical Trials 10, 647-652.
35. Simes, R. J. (1986). An improved Bonferroni procedure for multiple tests of significance. Biometrika 73, 751-754.
36. Song, Y. and Chi, G. Y. H. (2007). A method for testing a prespecified subgroup in clinical trials. Statistics in Medicine 26, 3535-3549.
37. Stallard, N., Hamborg, T., Parsons, N. and Friede, T. (2014). Adaptive Designs for Confirmatory Clinical Trials with Subgroup Selection. Journal of Biopharmaceutical Statistics 24, 1168-187.
38. Stallard, N., Posch, M., Friede, T., Koenig, F. and Brannath, W. (2009). Optimal choice of the number of treatments to be included in a clinical trial. Statistics in Medicine 28, 1321-1338.
39. Wang, S. J., O'Neill, R. T. and Hung, J. H. M. (2007). Approaches to evaluation of treatment effect in randomized clinical trials with genomic subset. Pharmaceutical Statistics 6, 277-244.
40. Wang, S. J., Hung, J. H. M., O'Neill, R. T. (2009). Adaptive patient enrichment designs in therapeutic trials. Biometrical Journal 71, 358-374.
41. Ziegler, A., Koch, A., Krockenberger, K. and Großhennig, A. (2012). Personalized medicine using DNA biomarkers: a review. Human Genetics 131, 1627-1638.